Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the sale, the insider now owns 1,174,662 shares in the company, valued at approximately $18,818,085.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $15.38 on Tuesday. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $17.85. The stock has a market cap of $1.34 billion, a PE ratio of -6.46 and a beta of -1.48. The firm has a fifty day moving average price of $15.22 and a 200 day moving average price of $13.75.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on DAWN shares. JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Monday. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $39.83.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently bought and sold shares of DAWN. SG Americas Securities LLC increased its holdings in shares of Day One Biopharmaceuticals by 58.7% during the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock valued at $454,000 after purchasing an additional 13,683 shares in the last quarter. Bank of New York Mellon Corp grew its position in Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after buying an additional 8,522 shares in the last quarter. TD Asset Management Inc raised its position in shares of Day One Biopharmaceuticals by 100.0% in the third quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock worth $677,000 after acquiring an additional 27,598 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in Day One Biopharmaceuticals by 89.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock worth $660,000 after purchasing an additional 25,414 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.